Medanta Reports Strong FY26 Growth Amid Ambitious Expansion

Medanta, operated by Global Health Limited, announced robust financial results for fiscal year 2026, with total income growing 20% to INR 45,089 million. The company's consolidated Profit After Tax (PAT) rose 15.1% to INR 5,541 million.

Reader Takeaway: Expansion fuels growth, but initial costs for the new Noida hospital are affecting near-term profitability.

Financial Highlights

Global Health Limited released its fourth-quarter and full fiscal year 2026 results on May 15, 2026. For FY26, total income reached INR 45,089 million, a 20% increase year-over-year. Consolidated PAT grew 15.1% to INR 5,541 million. The company reported its highest-ever quarterly revenue and EBITDA in Q4 FY26. Significant capacity expansion occurred, with 623 new beds added in FY26, and international revenue increased by 33%.

Strategic Growth Drivers

These results underscore strong operational performance and successful capacity expansion, vital for healthcare providers. Medanta's investments in new facilities, such as the Noida hospital, and its focus on high-margin specialties are key to future growth. The company's aggressive five-year expansion plan signals a clear strategy to scale operations and increase market share.

Backstory: New Facilities and Mature Growth

The 550-bed Noida facility, opened in November 2025, is projected to reach breakeven in the second half of FY27. Medanta has also been acquiring land for new hospitals, including a planned 400+ bed facility in Guwahati. Its established hospitals in Lucknow and Patna continue to show strong year-over-year growth, demonstrating effective operational scaling.

Future Expansion Plans

Medanta is preparing for substantial growth, planning to add approximately 3,200 beds over the next five years through both existing facility upgrades (brownfield) and new constructions (greenfield). This expansion will involve a capital expenditure of around INR 45,000 million. Capital expenditure for FY27 and FY28 is expected to be between INR 800-900 crore and INR 600-700 crore, respectively. The Noida facility is anticipated to improve its financial contribution as more insurance and government schemes are empanelled.

Key Risks to Monitor

Potential challenges include intense competition for skilled medical professionals, which could lead to rising wage costs. Geopolitical instability might temporarily affect medical tourism. The new Noida hospital incurred initial operating losses of INR 783 million in FY26, currently impacting consolidated margins until the facility reaches its breakeven point.

Peer Context

While specific peer comparisons were not detailed, Medanta's strategy focuses on expanding bed capacity and specializing in complex medical procedures. The healthcare industry generally competes on clinical expertise, service quality, and pricing. Medanta aims to differentiate itself through its focus on high-margin specialties and advanced treatments like robotic surgery and TAVI.

Key Performance Metrics (FY26)

• Total Income: INR 45,089 million (up 20% YoY)
• Consolidated PAT: INR 5,541 million (up 15.1% YoY)
• Q4 FY26 Revenue: Achieved highest quarterly revenue on record.
• Q4 FY26 EBITDA: Achieved highest quarterly EBITDA on record.
• Beds Added in FY26: 623 (a 20.5% increase)
• International Revenue: INR 2,780 million (up 33% YoY)
• Noida Occupancy: Approximately 30%
• Noida Operating Loss (FY26): INR 783 million

Investor Focus Areas

Investors will closely monitor the operational ramp-up of the Noida facility and its progress towards breakeven in H2 FY27. Successful execution of the company's five-year expansion plan, including adding 3,200 beds and managing the associated capital expenditures, will also be key.